Optimi Health Completes Pre-Clinical Trial Application Meeting
(firmenpresse) - Company Advised by Health Canada to Proceed with Phase 1 Psilocybin Study Application
VANCOUVER, BC (June 15, 2021) - Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (Optimi or the Company), a vertically integrated mushroom product developer and research partners with Numinus Wellness Inc., a mental health care company advancing innovative treatments and therapies, have been advised by their clinical trials administrators that they have received Health Canada approval to proceed with a formal submission to initiate their previously proposed phase 1 study.
The administrators of the IMPACT Clinical Trials Accelerator at the University of Calgary (IMPACT) engaged with Health Canada representatives on June 9, 2021, to discuss Optimis preliminary information package submitted as part of a pre-clinical trial application (CTA) including investigational product chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from Psilocybe mushrooms.
Michelle Nelson, PhD, CAPM, Senior Manager, Business Development and Strategic Planning for the IMPACT program notes, We have been given the green light to submit the formal application for the proposed phase I dosing study from Health Canada and are on track to initiate the trial in Q3 of this year. Health Canada indicated they have no concerns over the plan as presented, and theyve clarified that the next step is now to submit the formal application to receive approval to move ahead with a phase I study. In parallel with this, we will continue to further outline the required non-clinical testing that will be needed as we continue to develop the product and move forward into phase II and larger phase III trials in the future.
Concurrent efforts in recent weeks include cultivation, research, formulation development, and ongoing validation studies to produce the investigational psilocybin extract proposed for the phase I study. These efforts are being undertaken at the Health Canada-licensed Numinus lab in British Columbia, Canada.
Weitere Infos zu dieser Pressemeldung:
Insofar as the development work will be undertaken at the Numinus facility, Optimi will retain 100% ownership of the resulting all-natural psilocybin product and full intellectual property rights to its use.
Optimi Chairman of the Board JJ Wilson states, The team at IMPACT have been extremely thorough and professional in their preparatory efforts and their commitment to scientific and regulatory oversight. This a rapidly evolving field of research and our confidence in utilizing all-natural products as the superior solution compared to synthetics drives us to ensure our methods and formulations are the very best they can be. We aim to enter a growing marketplace where the need is increasingly pronounced because of the current pandemic. Thousands, perhaps tens of thousands of individuals stand to benefit from the efforts we are undertaking. This is important work, and in combination with our efforts at our soon-to-be completed facilities, advancement of our lineup of functional retail products, and ongoing R&D with Numinus, we are very pleased by the overall progress to-date.
On Behalf of the Board of Directors, Optimi Health Corp.
President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealers license under Canadas Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Find out more at: https://optimihealth.ca/.
FOR FURTHER INFORMATION CONTACT:
Phone: +1 (778) 930-1321
This news release contains forwardlooking statements and forwardlooking information within the meaning of Canadian securities legislation (collectively, "forwardlooking statements") that relate to Optimis current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forwardlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward looking statements pertaining to the dealers license application, activities proposed to be conducted under the Companys research exemption and associated business related to Psilocybin and Psilocin and Optimis plans, focus and objectives.
Forwardlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimis control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID19 pandemic and other factors set forth under ForwardLooking Statements" and Risk Factors in the Companys Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardlooking statement. Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
"> " alt="Adventus and Salazar Announce Drilling Results at the El Domo Deposit Highlighted by 26.8% Copper Equivalent Over 9.1 Metres
Datum: 15.06.2021 - 09:02 Uhr
Anzahl Zeichen: 6458
Typ of Press Release:
type of sending:
Date of sending:
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Optimi Health Completes Pre-Clinical Trial Application Meeting
steht unter der journalistisch-redaktionellen Verantwortung von
Optimi Health Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).